Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function.

Tulis DA, Bohl Masters KS, Lipke EA, Schiesser RL, Evans AJ, Peyton KJ, Durante W, West JL, Schafer AI.

Biochem Biophys Res Commun. 2002 Mar 8;291(4):1014-21.

PMID:
11866467
2.

Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells.

Yu SM, Cheng ZJ, Guh JH, Lee FY, Kuo SC.

Biochem J. 1995 Mar 15;306 ( Pt 3):787-92. Erratum in: Biochem J 1997 Mar 15;322(Pt 3):951. Retraction in: Cheng ZJ, Guh JH, Lee FY, Kuo SC. Biochem J. 1998 Oct 1;335 ( Pt 1):191.

3.

YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation.

Tulis DA, Durante W, Peyton KJ, Chapman GB, Evans AJ, Schafer AI.

Biochem Biophys Res Commun. 2000 Dec 20;279(2):646-52.

PMID:
11118339
4.
5.

Activation of soluble guanylyl cyclase by YC-1 in aortic smooth muscle but not in ventricular myocardium from rat.

Wegener JW, Gath I, Förstermann U, Nawrath H.

Br J Pharmacol. 1997 Dec;122(7):1523-9.

6.

Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle.

Wegener JW, Nawrath H.

Eur J Pharmacol. 1997 Mar 26;323(1):89-91.

PMID:
9105881
7.
8.

Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase.

Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, Strobel H, Wiemer G.

Br J Pharmacol. 1999 Nov;128(6):1316-22.

9.

YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets.

Friebe A, Müllershausen F, Smolenski A, Walter U, Schultz G, Koesling D.

Mol Pharmacol. 1998 Dec;54(6):962-7.

10.
11.

Salutary properties of YC-1 in the cardiovascular and hematological systems.

Tulis DA.

Curr Med Chem Cardiovasc Hematol Agents. 2004 Oct;2(4):343-59. Review.

PMID:
15320784
12.
13.

Inhibition of platelet adhesion to collagen by cGMP-elevating agents.

Wu CC, Ko FN, Teng CM.

Biochem Biophys Res Commun. 1997 Feb 13;231(2):412-6.

PMID:
9070290
14.
15.

YC-1 potentiates the antiplatelet effect of hydrogen peroxide via sensitization of soluble guanylate cyclase.

Wu CC, Kuo SC, Lee FY, Teng CM.

Eur J Pharmacol. 1999 Sep 24;381(2-3):185-91.

PMID:
10554886
16.

Decreased platelet deposition and smooth muscle cell proliferation after intramural heparin delivery with hydrogel-coated balloons.

Azrin MA, Mitchel JF, Fram DB, Pedersen CA, Cartun RW, Barry JJ, Bow LM, Waters DD, McKay RG.

Circulation. 1994 Jul;90(1):433-41.

PMID:
8026030
17.

Adenoviral gene transfer of fortilin attenuates neointima formation through suppression of vascular smooth muscle cell proliferation and migration.

Tulis DA, Mnjoyan ZH, Schiesser RL, Shelat HS, Evans AJ, Zoldhelyi P, Fujise K.

Circulation. 2003 Jan 7;107(1):98-105.

18.

Platelet inhibition by an L-arginine-derived substance released by IL-1 beta-treated vascular smooth muscle cells.

Durante W, Schini VB, Scott-Burden T, Junquero DC, Kroll MH, Vanhoutte PM, Schafer AI.

Am J Physiol. 1991 Dec;261(6 Pt 2):H2024-30.

PMID:
1661096
19.
20.
Items per page

Supplemental Content

Support Center